Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy

References

• Alibolandi M, Taghdisi SM, Ramezani P, et al. (2017). Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Int J Pharm 519:352–64.
   PubMed Web of Science ®Google Scholar
• Botella P, Rivero-Buceta E. (2017). Safe approaches for camptothecin delivery: structural analogues and nanomedicines. J Control Release 247:28–54.
   PubMed Web of Science ®Google Scholar
• Bradley MO, Swindell CS, Anthony FH, et al. (2001a). Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 74:233–6.
   PubMed Web of Science ®Google Scholar
• Bradley MO, Webb NL, Anthony FH, et al. (2001b). Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229–38.
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotech 6:815–23.
   PubMed Web of Science ®Google Scholar
• Cao Z, Kozielski A, Liu X, et al. (2009). Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts. Cancer Res 69:4742–9.
   PubMed Web of Science ®Google Scholar
• Cheetham AG, Chakroun RW, Ma W, Cui H. (2017). Self-assembling prodrugs. Chem Soc Rev 46:6638–63.
   PubMed Web of Science ®Google Scholar
• Cheikh-Ali Z, Caron J, Cojean S, et al. (2015). “Squalenoylcurcumin” nanoassemblies as water-dispersible drug candidates with antileishmanial activity. Chem Med Chem 10:411–8.
   Web of Science ®Google Scholar
• Dong D, Hsiao C-H, Giovanella BC, et al. (2019). Sustained delivery of a camptothecin prodrug-CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity. Int J Nanomed 14:3799–817.
   PubMed Web of Science ®Google Scholar
• Dosio F, Reddy LH, Ferrero A, et al. (2010). Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. Bioconjugate Chem 21:1349–61.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. (2011). “The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–51.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. (2001). Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–8.
   PubMed Web of Science ®Google Scholar
• He WX, Hu X, Jiang W, et al. (2017). Rational design of a new self-codelivery system from redox-sensitive camptothecin-cytarabine conjugate assembly for effectively synergistic anticancer therapy. Adv Healthcare Mater 6:1700829.
   Web of Science ®Google Scholar
• He WX, Jiang Y, Li Q, et al. (2019). A versatile strategy to create an active tumor-targeted chemo-photothermal therapy nanoplatform: a case of an IR-780 derivative co-assembled with camptothecin prodrug. Acta Biomater 84:356–66.
   PubMed Web of Science ®Google Scholar
• He CL, Zhuang XL, Tang ZH, et al. (2012). Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv Healthcare Mater 1:48–78.
   Web of Science ®Google Scholar
• Jang D-J, Moon C, Oh E. (2016). Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. Biomed Pharmacother 80:162–72.
   PubMed Web of Science ®Google Scholar
• Kunii R, Onishi H, Machida Y. (2007). Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 67:9–17.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen Y, Huang Y, et al. (2019). Kinetic stability-driven cytotoxicity of small-molecule prodrug nanoassemblies. J Mater Chem B 7:5563–72.
   PubMed Web of Science ®Google Scholar
• Li Y, Kang T, Wu Y, et al. (2018a). Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy. Chem Commun 54:1996–9.
   PubMed Web of Science ®Google Scholar
• Lin R, Cui H. (2015). Supramolecular nanostructures as drug carriers. Curr Opin Chem Eng 7:75–83.
   Web of Science ®Google Scholar
• Liu J, Jiang Z, Zhang S, Saltzman WM. (2009). Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 30:5707–19.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu J, Kang T, et al. (2018b). Co-assembling FRET nanomedicine with self-indicating drug release. Chem Commun 54:11618–21.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu C, Wang P, et al. (2015). The self-assembling camptothecin-tocopherol prodrug: an effective approach for formulating camptothecin. Biomaterials 62:176–87.
   PubMed Web of Science ®Google Scholar
• Luo C, Sun J, Sun B, et al. (2016). Facile fabrication of tumor redox-sensitive nanoassemblies of small-molecule oleate prodrug as potent chemotherapeutic nanomedicine. Small 12:6353–62.
   PubMed Web of Science ®Google Scholar
• Ma Y, Mou Q, Zhu X, Yan D. (2017). Small molecule nanodrugs for cancer therapy. Mater Today Chem 4:26–39.
   Web of Science ®Google Scholar
• Maksimenko A, Dosio F, Mougin J, et al. (2014). A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci USA 111:E217–26.
   PubMed Web of Science ®Google Scholar
• Martino E, Della Volpe S, Terribile E, et al. (2017). The long story of camptothecin: from traditional medicine to drugs. Bioorg Med Chem Lett 27:701–7.
   PubMed Web of Science ®Google Scholar
• Schmid D, Jarvis GE, Fay F, et al. (2014). Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death Dis 5:e1454.
   PubMed Web of Science ®Google Scholar
• Tang X-J, Han M, Yang B, et al. (2014). Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin. Int J Pharm 477:536–45.
   PubMed Web of Science ®Google Scholar
• Thomas CJ, Rahier NJ, Hecht SM. (2004). Camptothecin: current perspectives. Bioorganic Med Chem 12:1585–604.
   PubMed Web of Science ®Google Scholar
• Tian X, Minh N, Foote HP, et al. (2017). CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1 alpha. Cancer Res 77:112–22.
   PubMed Web of Science ®Google Scholar
• Ueki K, Onishi H, Sasatsu M, Machida Y. (2009). Preparation of carboxy-PEG-PLA nanoparticles loaded with camptothecin and their body distribution in solid tumor-bearing mice. Drug Dev Res 70:512–9.
   Web of Science ®Google Scholar
• Wang YJ, Liu D, Zheng QC, et al. (2014). Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett 14:5577–83.
   PubMed Web of Science ®Google Scholar
• Wang J, Mao W, Lock LL, et al. (2015). The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano 9:7195–206.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang Y, Liu X, Zhang W, et al. (2017). Camptothecin-based nanodrug delivery systems. Cancer Biol Med 14:363–70.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Donehower RC, Carducci MK, et al. (2003). Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589–97.
   PubMed Web of Science ®Google Scholar
• Yu GC, Zhao XL, Zhou J, et al. (2018). Supramolecular polymer-based nanomedicine: high therapeutic performance and negligible long-term immunotoxicity. J Am Chem Soc 140:8005–19.
   PubMed Web of Science ®Google Scholar
• Zeng J, Li C, Duan X, et al. (2019). PEGylation of lipophilic SN38 prodrug with DSPE-mPEG2000 versus cremophor EL: comparative study for intravenous chemotherapy. Drug Deliv 26:354–62.
   PubMed Web of Science ®Google Scholar
• Zhan H, Zhou X, Cao Y, et al. (2017). Anti-cancer activity of camptothecin nanocrystals decorated by silver nanoparticles. J Mater Chem B 5:2692–701.
   PubMed Web of Science ®Google Scholar
• Zhang SW, Guan JB, Sun MC, et al. (2017a). Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy. Drug Deliv 24:1460–9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo Y, Ding F, et al. (2019). A camptothecin-grafted DNA tetrahedron as a precise nanomedicine to inhibit tumor growth. Angew Chem 58:13794–8.
   Google Scholar
• Zhang FW, Zhu GZ, Jacobson O, et al. (2017b). Transformative nanomedicine of an amphiphilic camptothecin prodrug for long circulation and high tumor uptake in cancer therapy. Acs Nano 11:8838–48.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yan X, Wang Y, et al. (2019). Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy. J Mater Chem B 7:265–76.
   PubMed Web of Science ®Google Scholar